Articles

Panelists discuss the challenges of the pandemic and its impact on the risk for pandemic-related disruptions in cancer care, breast cancer diagnosis, timing and choice of treatment, and mental health. Read More ›

De-escalation of adjuvant cytotoxic chemotherapy among patients who experienced pathologic complete response in early-stage HER2-positive breast cancer appears to be an acceptable approach for both patients and physicians. Read More ›

Minority women need timely, high-quality access to care, as delays in diagnosis and treatment may be fatal. Patients and clinicians need to work together to overcome obstacles, so they can gain access to the best screening, genetic testing, and treatments through clinical trials. Read More ›

Based on the premise that BCL-2 may play a key role in HER2-positive breast cancer, a phase 1b/2, randomized, placebo-controlled trial will evaluate venetoclax plus trastuzumab emtansine. Read More ›

In patients with HER2-expressing metastatic breast cancer, Enhertu (trastuzumab deruxtecan) plus Opdivo (nivolumab) demonstrated antitumor activity consistent with previous studies of Enhertu and had an acceptable safety profile in this short-term analysis. Read More ›

In the HER2-positive metastatic breast cancer setting, trastuzumab-based therapy can support a full recovery. In patients who have achieved a long-term complete response, discontinuation of therapy may be considered appropriate. Read More ›

For patients with breast cancer, adhering to a diabetes risk reduction diet improved survival when compared with patients who did not follow this diet. Read More ›

In this study of the impact of tucatinib in patients with HER2-positive metastatic breast cancer with stable and active brain metastases, health-related quality of life was maintained, while significant and clinically meaningful improvement in overall survival was observed. Read More ›

To reduce depressive symptoms, behavioral intervention techniques of mindfulness mediation and survivorship education are helpful, according to results from a recent randomized, controlled clinical trial. Read More ›

Retreatment with pertuzumab as either third- or fourth-line chemotherapy was both effective and reasonable in patients with HER2-positive locally advanced/metastatic breast cancer and may be considered a standard treatment practice. Read More ›